Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells
Cells · 07.06.2026 · 15 (12) · 1045
DOI: 10.3390/cells15121045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 07.06.2026. Verfasst von Mariana Pereira und 1 weiteren Autor:innen. Beteiligte Einrichtung: PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. Hauptthemen laut MEDLINE: Drug Repositioning, Prostatic Neoplasms, Urinary Bladder Neoplasms, Reverse Transcriptase Inhibitors. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FCT—Fundação para a Ciência e a Tecnologia, FEDER—Fundo Europeu de Desenvolimento Regional.
Abstract (Originalsprache)
Drug repurposing presents as a promising strategy in oncology, particularly for urological prostate and bladder cancers, where resistance to current therapy remains a challenge. This study evaluated the anticancer potential of three antiretroviral drugs, namely ritonavir (RIT), saquinavir (SAQ), and rilpivirine (RPV), in PC-3 and UM-UC-5 cancer cell lines, using MTT, clonogenic, wound healing, toxicity assessment with fibroblast cells, and DCFDA assays; this last method included efavirenz (EFV) and etravirine (ETV) for intracellular reactive oxygen species (ROS) production. RIT and SAQ showed stronger antiproliferative effects than RPV, with lower concentration- and cell-line-dependent activity, while clonogenic assays confirmed a reduction in long-term proliferation, particularly for RIT in both cell lines and SAQ for UM-UC-5. In contrast, effects on cell migration were limited for all drugs. ROS production was cell-dependent, with EFV increasing ROS in PC-3 and SAQ and RIT in UM-UC-5 cells. Generally, all drugs showed minimal toxicity in non-malignant cells, with SAQ exhibiting some toxicity but only for concentrations higher than those required for anticancer activity. Overall, these findings suggest that antiretroviral, especially protease inhibitors, may cause anticancer effects, although these are concentration- and context-dependent, and further investigation is needed to understand the mechanisms involved.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.
- ICBAS-School of Medicine and Biomedical Sciences, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
- RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
- Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
ORCID-Profile: Mariana Pereira, Nuno Vale
Förderung
- FCT—Fundação para a Ciência e a Tecnologia
- FEDER—Fundo Europeu de Desenvolimento Regional
Zitieren
APA
Pereira, M., & Vale, N. (2026). Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells. Cells, 15(12), 1045. https://doi.org/10.3390/cells15121045
Vancouver
Pereira M, Vale N. Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells. Cells. 2026;15(12):1045. doi:10.3390/cells15121045
BibTeX
@article{Pereira2026,
author = {Pereira, Mariana and Vale, Nuno},
title = {Repurposing Antiretroviral Drugs for Urological Cancers: Differential Effects of Protease Inhibitors and NNRTIs on Prostate and Bladder Cancer Cells},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1045},
doi = {10.3390/cells15121045}
}
EUVIMED